| Document |
Document Title |
|
WO/2023/013409A1 |
The present disclosure relates to providing a cytoprotectant and a thermal oxidation inhibitor that protect the skin from infrared damage and heat damage. More particularly, there are provided a cytoprotectant and a thermal oxidation inh...
|
|
WO/2023/013787A1 |
Provided is a nucleic acid structure that enhances an allergen-specific immune response. The nucleic acid structure includes a polynucleotide that codes for a SNARE protein and a polynucleotide that codes for an allergen.
|
|
WO/2023/012092A1 |
The present invention relates to a combined preparation comprising an acid alpha-glucosidase (GAA) enzyme and at least one allosteric chaperone of the acid alpha-glucosidase enzyme selected from the group consisting of L-carnitine, D-car...
|
|
WO/2023/013700A1 |
Provided is a novel activity regulator which can regulate the activity of a T cell and/or a B cell. An activity regulator for a T cell and/or a B cell contains progesterone or a derivative thereof as an active ingredient.
|
|
WO/2023/008459A1 |
This medicament characterized by containing, together or separately in combination with a HDAC inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein is useful as a medicament for treatmen...
|
|
WO/2023/009453A1 |
Disclosed are devices, systems and methods for neural signal detection of immune responses. In some aspects, a system includes a processing unit; a receiving unit configured to receive at least one sensor signal from a wearable sensor, w...
|
|
WO/2023/008470A1 |
The present invention provides a fused-ring amine derivative that has a DYRK inhibiting action and that is represented by formula (1) (refer to the description with respect to A1, L1, T, Z, and I in the formula), or a pharmaceutically ac...
|
|
WO/2023/008218A1 |
The present invention provides a material that has an excellent functionality and a high water solubility, and that can be used in cosmetics, pharmaceuticals, and food and drink items, etc. The present invention is a hyaluronidase inhi...
|
|
WO/2023/009585A2 |
Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or...
|
|
WO/2023/008461A1 |
The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antib...
|
|
WO/2023/008472A1 |
The present invention provides a benzothiazole derivative represented by formula (I) (in the formula, A1, L and Q are as defined in the description) or a pharmaceutically acceptable salt thereof, which exhibits a DYRK inhibitory activity...
|
|
WO/2023/009612A1 |
Provided herein are acoramidis (3-(3-(3,5-dimethyl-lH-pyrazol-4-yl) propoxy)-4-fluorobenzoic acid) derivatives of formula (I) wherein A is having activity against transthyretin (TTR) related conditions. Also provided are the compounds fo...
|
|
WO/2023/008462A1 |
The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antib...
|
|
WO/2023/008553A1 |
The purpose of the present invention is to provide a new molecule neutralizing bonding between ACE2 and the RBD of the spike protein of a corona virus variant. The present invention provides a chicken antibody binding to the spike protei...
|
|
WO/2023/007779A1 |
The present invention provides a pharmaceutical composition for treating peripheral nerve injury, said pharmaceutical composition comprising a substance that inhibits the formation of neutrophil extracellular traps (NETs) outside the par...
|
|
WO/2023/008577A1 |
The present invention addresses the problem of providing a Ras/Raf binding inhibitor compound that has the effect of inhibiting Ras/Raf signaling in drug-resistant cancer cells and in a wide range of Ras mutant cancers. A Ras/Raf binding...
|
|
WO/2023/007994A1 |
[Problem] To provide an oxygen enema composition and therapeutic method by which it is possible to have a patient safely and efficiently absorb oxygen through the intestines. [Solution] An oxygen enema composition containing a dissolved ...
|
|
WO/2023/009444A1 |
This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in n...
|
|
WO/2023/008570A1 |
Provided herein is a pharmaceutical composition for treating cancer, the pharmaceutical composition containing: a folic acid-modified hydroxyalkylated cyclodextrin selected from the group consisting of folic acid-modified hydroxypropylcy...
|
|
WO/2023/006108A1 |
The present invention provides a preparation method for sodium hyaluronate having full molecular weight distribution, the method comprising: step 1): spraying hydrogen peroxide and performing ultraviolet irradiation on a sodium hyalurona...
|
|
WO/2023/008585A1 |
The present invention relates to novel crystalline forms of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-
yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride (HCl-salt), and to pharmaceutical compositions t...
|
|
WO/2023/008858A1 |
The present invention relates to a method for prevention or treatment of fibrotic disease, wherein an antibody binding specifically to thrombospondin-2 (TSP-2) protein involved in fibrosis is used for predicting the onset of fibrotic dis...
|
|
WO/2023/008533A1 |
The present invention provides a pharmaceutical composition that, with respect to pancreatic cancer and bile duct cancer, suppresses cell proliferation and has an anti-cancer effect. The present invention pertains to: a pharmaceutical co...
|
|
WO/2023/001161A1 |
A ganoderma spore oil and a use thereof in the preparation of a drug for counteracting cancer-related fatigue. The content of triglyceride components in the ganoderma spore oil is greater than 90%. Ganoderma triterpenoid compounds are no...
|
|
WO/2023/000350A1 |
Glycerol phenylbutyrate granules, comprising the following components in percentage by mass: 5%-15% of glycerol phenylbutyrate, 5%-45% of a solid carrier, 40%-80% of a filler, 1%-5% of an adhesive, 0.5%-3% of a disintegrating agent, 0.1%...
|
|
WO/2023/002983A1 |
The present disclosure includes a method for determining the sensitivity of a cancer patient to an FGFR inhibitor, wherein the method includes examining the FGFR/EGFR expression ratio in the cancer of a patient and comparing the FGFR/EGF...
|
|
WO/2023/285349A1 |
The present invention relates to Carnitine-Palmitoyl-Transferase-1 (CPT-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject. The invention also relates to pharmaceutical compositions comprising a Car...
|
|
WO/2023/286694A1 |
There are said to be approximately five million people worldwide who suffer from inflammatory bowel diseases including ulcerative colitis and Crohn's disease, and the development of therapeutic agents is hoped for. In particular, the dev...
|
|
WO/2023/288210A1 |
Provided are methods for the treatment of Fabry disease in adolescent patient.
|
|
WO/2023/286823A1 |
The present invention provides a pharmaceutical composition which contains: an LAT1 inhibitor, such as 5-phenyl-5-[4-(trifluoromethyl)phenoxy]pentan-1-amine or a 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid or a pharmaceutically accept...
|
|
WO/2023/286834A1 |
The present invention addresses the problem of providing: pericyte-like cells that express VEGF at a high level, have high angiogenesis ability, and have high cell proliferating ability as compared to primary pericytes that have been usa...
|
|
WO/2023/286792A1 |
[Problem] The purpose of the present invention is to provide a method in which a substance capable of promoting the production of hyaluronic acid is ingested to compensate for the decline in hyaluronic acid indirectly rather than a metho...
|
|
WO/2023/287251A1 |
The present invention relates to an HIF-1α expression or activity inhibitor. The HIF-1α expression or activity inhibitor of the present invention effectively suppresses the expression of HIF-1α in the eyeball, and down-regulates the e...
|
|
WO/2023/286754A1 |
Provided is a composition which comprises ingredients that are easy to ingest on a daily basis and is effective in activating autophagy in intestinal epithelial cells or intestinal epithelial stem cells. Provided is an autophagy-activati...
|
|
WO/2023/286305A1 |
The present invention addresses the problem of providing: a cell quality management method whereby a cell having a pharmacological activity can be selected; and a cell production method utilizing the quality management method. According ...
|
|
WO/2023/286474A1 |
Provided are an anti-aging agent including a placenta extract as non-degraded placenta, a cosmetic in which the anti-aging agent is blended, a medicine in which the anti-aging agent is blended and which has a preventive effect and/or the...
|
|
WO/2023/281095A1 |
The invention concerns a compound of formula (I), wherein R1 = halogen atom selected in the group consisting of: F, Cl, Br, I, and R2 = H or OH, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing ...
|
|
WO/2023/281787A1 |
The present invention is a method for using a lactic acid bacterium to produce spermidine, the bacterium releasing intracellularly produced spermidine to the outside of the cell.
|
|
WO/2023/282296A1 |
The present invention provides: a pH-responsive lipid derivative represented by the structure shown in a formula (i) (where each symbol in the formula is as defined in the description); and a pH-responsive carrier that is useful as a car...
|
|
WO/2023/282379A1 |
The present invention relates to a formulation composition for enhancing the efficacy of probiotics, comprising an unsaturated fatty acid mixture and probiotics. The formulation composition for enhancing the efficacy of probiotics, compr...
|
|
WO/2023/280615A1 |
The invention is in the field of medical treatments, in particular the treatment of humans, more in particular humans with calcium deposition diseases. In one aspect, the invention provides polypeptides that prevent or decrease the preci...
|
|
WO/2023/282306A1 |
The present invention provides a pharmaceutical composition for treating or preventing a disease associated with the reduction or defect of the modification of 5-taurinomethyluridine (τm5U) in mitochondrial tRNA, the pharmaceutical comp...
|
|
WO/2023/281248A1 |
The disclosure relates to a method of treating a disorder of the tyrosine degradation pathway in a subject, and a composition for use in said method. The disclosure also relates to a nucleic acid silencing molecule that reduces the expre...
|
|
WO/2023/282702A1 |
Provided are an inhibitor of SHP2, a pharmaceutical composition for preventing or treating diseases related to SHP2 comprising same, a method for treating and preventing diseases using same, and a use thereof. According to the present in...
|
|
WO/2023/282145A1 |
Provided is a composition for preventing or treating tissue aging which contains an S-adenosylmethionine synthase inhibitor. Also provided is a method for screening an anti-aging substance, the method comprising (1) a step for culturing ...
|
|
WO/2023/281034A1 |
The present invention relates to the treatment of acidosis related diseases. In this study, the inventors have investigated how human monocytes adapt, survive and differentiate into macrophages under lactic acidosis. Experiments were con...
|
|
WO/2023/281103A1 |
The invention concerns a compound of formula (I), R1 = H or halogen atom selected in the group consisting of: F, Cl, Br, I, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating Klein...
|
|
WO/2023/282269A1 |
Disclosed is a prophylactic or therapeutic drug for Parkinson's disease, which comprises a trisulfide compound and is characterized by being administered in combination with a drug that is used for a dopamine supplementation therapy.
|
|
WO/2023/276167A1 |
The purpose of the present invention is to provide an excellent sirtuin activator. This excellent sirtuin activator can be provided by combining Kaempferia parviflora, a Kaempferia parviflora extract, or a polyalkoxyflavonoid compound ...
|
|
WO/2023/277122A1 |
The purpose of the present invention is to provide a technique for detecting or separating polysialic acid or a polysialic acid-carrying body. Provided is at least one antibody selected from the group consisting of antibodies A to E.
|
